Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSans Pola, Carla
dc.contributor.authorAgustí Escasany, Maria Antònia
dc.contributor.authorBosch Gil, José Ángel
dc.contributor.authorAgraz Pamplona, Irene
dc.contributor.authorAlerany Pardo, Carme
dc.contributor.authorDanes Carreras, Immaculada
dc.date.accessioned2022-05-23T08:33:30Z
dc.date.available2022-05-23T08:33:30Z
dc.date.issued2021-10-26
dc.identifier.citationSans-Pola C, Agustí A, Bosch JA, Agraz I, Alerany C, Danés I, et al. Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study. J Clin Med. 2021 Oct 26;10(21):4941.
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/11351/7566
dc.descriptionClinical pharmacology; Glomerulonephritis; Rituximab
dc.description.abstractOff-label use of rituximab is commonly requested for patients with resistant nephropathies. The outcomes and tolerability of rituximab in adult patients with nephropathy treated at our hospital (from 2013 to 2018) were described. Data were retrieved from electronic medical records. Response was classified as complete remission (CR), partial remission (PR), or no response (NR) according to the KDIGO criteria. A total of 89 requests were received for 61 patients. Median age was 58 years (45.9% female). Idiopathic membranous nephropathy (MN) (n = 30) was the most frequent indication, followed by minimal change disease (MCD) (n = 15) and secondary membranoproliferative glomerulonephritis (MPGN) (n = 12). Three patients with focal segmental glomerulosclerosis (FSGS) were included. After most treatment cycles in MN, a CR or PR was observed; median proteinuria levels significantly decreased for these patients (6000 mg/24h (IQR 3584–10,300) vs. 1468.8 (IQR 500–4604.25), p < 0.01). In MPGN, no response was documented after 46.7% of rituximab cycles. A CR or PR was described with the majority of rituximab cycles in MCD, with a significant decrease in proteinuria (6000 mg/24 h (IQR 4007–11,426) vs. 196.8 (IQR 100–1300), p = 0.013). No cycles produced a response in FSGS. Mean CD19+ B-cell decreased in all types of nephropathy (10.44% vs. 0.29%, p < 0.0001). Eleven patients presented infusion-related reactions, and 17 presented infectious complications. The majority of patients with MN and MCD had complete or partial responses; however, neither MPGN nor FSGS had encouraging results.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;10(21)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectRonyons - Malalties - Tractament
dc.subjectPersones grans - Assistència mèdica
dc.subject.meshKidney Diseases
dc.subject.mesh/drug therapy
dc.subject.meshTertiary Healthcare
dc.titleOff-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm10214941
dc.subject.decsenfermedades renales
dc.subject.decs/farmacoterapia
dc.subject.decsatención terciaria de la salud
dc.relation.publishversionhttps://doi.org/10.3390/jcm10214941
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Sans-Pola C, Agustí A, Danés I] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca en Malalties Immunomediades i Teràpies Innovadores, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bosch JÀ] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina Interna, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Agraz I] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Alerany C] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34768461
dc.identifier.wos000720088100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record